Research Papers

This database includes peer-reviewed publications authored or funded by TB Alliance. Use the tags on the right to filter by subject, or search for a particular author or term using the search bar.

Displaying 132 papers

Lead optimization of 1,4-azaindoles as antimycobacterial agents

6/2014 - Shirude PS, Shandil RK, Manjunatha MR, et. al. Lead optimization of 1,4-azaindoles as antimycobacterial agents. J Med Chem. 2014 Jul 10;57(13):5728-37. doi: 10.1021/jm500571f.

Tags: Drug Discovery, Pharmacokinetics

1,4-Azaindole, a Potential Drug Candidate for Treatment of Tuberculosis

6/2014 - Chatterji M, Shandil R, Manjunatha MR, et. al. 1,4-azaindole, a potential drug candidate for treatment of tuberculosis.Antimicrob Agents Chemother. 2014 Sep;58(9):5325-31. doi: 10.1128/AAC.03233-14.

Tags: Bedaquiline (TMC-207), Drug Discovery, MDR-TB, Pharmacokinetics, Preclinical Data, Pretomanid/PA-824

Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents

4/2014 - Zhang D, Liu Y, Zhang C, et. al. Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents. Molecules. 2014 Apr 9;19(4):4380-94. doi: 10.3390/molecules19044380.

Tags: Clofazamine, Pharmacodynamics, Pharmacokinetics

Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

4/2014 - Gillespie SH, Crook AM, McHugh TD, et. al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1577-87. doi: 10.1056/NEJMoa1407426.

Tags: Clinical Development, Clinical Trial Results, HRZE, Moxifloxacin, ReMoxTB

Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects

11/2013 - Winter H, Ginsberg A, Egizi E, et. al. Effect of a High-Calorie, High-Fat Meal on the Bioavailability and Pharmacokinetics of PA-824 in Healthy Adult Subjects. Antimicrob Agents Chemother. 2013 Nov; 57(11): 5516–5520. doi: 10.1128/AAC.00798-13

Tags: Clinical Development, Clinical Trial Results, Pharmacodynamics, Pretomanid/PA-824

Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents

10/2013 - Cooper CB. Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents. J Med Chem. 2013 Oct 24;56(20):7755-60. doi: 10.1021/jm400381v.

Tags: Drug Discovery, Global Pipeline, Preclinical Models

Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen

8/2013 - Dutta NK, Alsultan A, Gniadek TJ, et. al. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother. 2013 Aug;57(8):3910-6. doi: 10.1128/AAC.00761-13.

Tags: HRZE, Moxifloxacin, PaMZ, Preclinical Data, Pretomanid/PA-824, Pyrazinamide

The role of product development partnerships in advancing the development of drugs for unmet needs

6/2013 - Breitstein J, Spigelman M. The role of product development partnerships in advancing the development of drugs for unmet needs. Clin Pharmacol Ther. 2013 Jun;93(6):468-70. doi: 10.1038/clpt.2013.53.

Tags: Advocacy, Editorials, Global Pipeline

Requirements for the clinical evaluation of new anti-tuberculosis agents in children

6/2013 - Donald PR, Ahmed A, Burman WJ, et. al. Requirements for the clinical evaluation of new anti-tuberculosis agents in children. Int J Tuberc Lung Dis. 2013 Jun;17(6):794-9. doi: 10.5588/ijtld.12.0567.

Tags: Advocacy, Childhood TB, Clinical Development, Editorials, Trial Design

Engaging communities in tuberculosis research

6/2013 - Boulanger RF, Seidel S, Lessem E, et. al. Engaging communities in tuberculosis research. Lancet Infect Dis. 2013 Jun;13(6):540-5. doi: 10.1016/S1473-3099(13)70042-2.

Tags: Advocacy, Community Engagement, Editorials

Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients withsputum microscopy smear-positive pulmonary tuberculosis

5/2013 - Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et. al. Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary Tuberculosis. Antimicrob Agents Chemother.

Tags: Bedaquiline (TMC-207), Clinical Development, Clinical Trial Results, Pharmacokinetics

Identification of a small molecule with activity against drug-resistant and persistent tuberculosis

5/2013 - Wang F, Sambandan D, Halder R, et. al. Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):E2510-7. doi: 10.1073/pnas.1309171110.

Tags: Drug Discovery, Drug Targets, MDR-TB, Preclinical Models

Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects

4/2013 - Winter H, Egizi E, Erondu N, et. al. Evaluation of Pharmacokinetic Interaction between PA-824 and Midazolam in Healthy Adult Subjects. Antimicrob Agents Chemother. 2013 Aug; 57(8): 3699–3703.doi: 10.1128/AAC.02632-12

Tags: Clinical Development, Clinical Trial Results, Pretomanid/PA-824

Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents

3/2013 - Hwang JM, Oh T, Kaneko T., et. al. Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents. J Nat Prod. 2013 Mar 22;76(3):354-67. doi: 10.1021/np3007167.

Tags: Drug Discovery, Pharmacodynamics, Pharmacokinetics, Preclinical Data

Aligning New Tuberculosis Drug Regimens and Drug Susceptibility Testing- A Needs Assessment and Roadmap for Action

3/2013 - Wells WA, Boehme CC, Cobelens FGJ, et. al. Aligning New Tuberculosis Drug Regimens and Drug Susceptibility Testing: A Needs Assessment and Roadmap for Action. Lancet Infect Dis. 2013;13(5):449-458. doi:10.1016/S1473-3099(13)70025-2.

Tags: Advocacy, Drug-Sensitivity Testing, Editorials, TB Market

Reply to "Contradictory results with high-dosage rifamycin in mice and humans"

2/2013 - Nuermberger EL, Rosenthal IM, Tasneen R, et. al. Reply to "Contradictory results with high-dosage rifamycin in mice and humans". Antimicrob Agents Chemother. 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12

Tags: Drug Discovery, Editorials, Pharmacodynamics, Preclinical Models, Rifapentine

Early bactericidal activity of new drug regimens for tuberculosis - Authors' reply

1/2013 - Diacon AH, Donald PR, Mendel CM. Early bactericidal activity of new drug regimens for tuberculosis - Authors' reply. Lancet. 2013 Jan 12;381(9861):112-3. doi: 10.1016/S0140-6736(13)60042-2.

Tags: Clinical Development, Editorials, Moxifloxacin, NC-001, PaMZ, Pretomanid/PA-824, Pyrazinamide, Trial Design

Multidrug-resistant tuberculosis

11/2012 - D'Ambrosio L, Centis R, Migliori GB. Multidrug-resistant tuberculosis. N Engl J Med. 2012 Nov 29;367(22):2154; author reply 2155-6. doi: 10.1056/NEJMc1210001#SA1.

Tags: Advocacy, Clinical Development, Editorials, Trial Design

Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis

11/2012 - Franzblau SG, DeGroote MA, Cho SH, et. al. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb). 2012 Nov;92(6):453-88. doi: 10.1016/j.tube.2012.07.003.

Tags: Advocacy, Drug Discovery, Editorials, Preclinical Models

The multi-step process of building TB/HIV collaboration in Cambodia

10/2012 - Eang MT, Vun MC, Eam KK, et. al. The multi-step process of building TB/HIV collaboration in Cambodia. Health Res Policy Syst. 2012 Oct 18;10:34. doi: 10.1186/1478-4505-10-34.

Tags: Advocacy, Editorials, Policy, TB Market, TB-HIV

Pages